Company Insights

AQST supplier relationships

Explore interactive graphBrowse insights index
AQST supplier relationship map

AQST Supplier Relationships: What investors need to know

Aquestive Therapeutics (AQST) is a specialty pharmaceutical manufacturer that monetizes through contract manufacturing and licensing collaborations, producing thin-film drug delivery products and supplying formulation services to branded pharmaceutical partners. The company earns revenue by manufacturing partner products (including Suboxone® sublingual film) and by licensing technology and product rights into regional markets, with a mix of long-term manufacturing commitments and service contracts that drive recurring cash flows. For a deeper supplier-risk view and supplier mapping for investment decisions, visit https://nullexposure.com/.

How AQST’s commercial model actually works

Aquestive operates as a manufacturing-first, partner-focused business. It contracts with branded drug companies to produce oral thin films and related formulations, often under multi-year arrangements that convert development work into manufacturing revenue. The company both buys critical inputs—active pharmaceutical ingredients (APIs) and specialty thin-film foil—from approved vendors globally, and outsources key development and clinical tasks to third-party service providers. This hybrid operating posture positions AQST as a critical manufacturing node for partners, where contractual obligations and supply-chain continuity directly drive revenue realization.

Who AQST manufactures for and supplies: the current relationships

The most recent company business update (March 2026) lists active manufacturing collaborations with established pharma firms. Each relationship below is summarized in plain English with the reporting source.

What the relationship map implies about AQST’s operating constraints

Company disclosures and the relationship evidence reveal a set of structural operating constraints that shape AQST’s risk/reward profile:

  • Contracting posture and maturity: AQST holds multi-year commercial arrangements and facility leases extending through 2028 with renewal options to 2033, signaling a long-term manufacturing commitment and capital intensity in facilities. These long-term contracts underpin stable revenue but also lock in fixed-cost capacity. Company filings reference lease terms that extend through September 30, 2028 with renewal options to 2033.

  • Global sourcing and vendor diversity: AQST purchases raw materials and APIs from approved vendors “both domestically and internationally,” showing a global procurement footprint that diversifies supply risk geographically but increases exposure to cross-border logistics, tariffs, and regulatory inspections.

  • Critical single-source inputs: The company discloses that its thin film packaging foil is supplied by a single manufacturer and that qualified alternative thin film foil sources would be time consuming to qualify; the thin-film foil is therefore a critical, high-concentration supply risk that can cause material delays if disrupted.

  • Role mix and dependency: AQST performs as a manufacturer for partner products while simultaneously acting as a buyer for certain APIs (notably the Suboxone API supplied by Indivior), and as a service provider via third-party CRO relationships for clinical and development programs. This mixed role profile amplifies operational complexity: manufacturing obligations require tight supply reliability while service-provider relationships imply reliance on external expertise and data control.

  • Active relationship stage: Multiple disclosures confirm AQST’s manufacturing relationships are active today, indicating near-term revenue exposure tied to partner sales and ongoing production schedules.

Investment implications: risks and upside

AQST’s profile combines durable revenue from contract manufacturing with concentrated input risks that require active operational oversight.

  • Upside: Long-term contracts and multinational partners provide predictable revenue streams and scale benefits for thin-film manufacturing capability. AQST’s role in producing high-profile products like Suboxone® supports stable cash generation while the firm commercializes additional proprietary products.

  • Key risks: The single-supplier foil situation and reliance on third-party API sourcing for marquee products are material operational risks that can lead to production delays and revenue interruptions. The requirement to obtain Suboxone API directly from Indivior creates contractual dependency that constrains AQST’s procurement flexibilities. Investors should price in potential supply interruptions and the time-consuming qualification process for alternative suppliers.

Consider these targeted operational indicators:

  • Concentration risk from single-source foil supplier and required partner-supplied APIs.
  • Contract longevity that supports revenue but raises fixed-cost exposure.
  • Service-provider reliance (CROs, MSSP for cybersecurity) that limits direct control over certain functions.

For granular supplier mapping and credit exposure analysis, see our platform: https://nullexposure.com/.

Practical takeaways for investors and operators

  • Monitor vendor qualification progress: Any routine updates on additional qualified thin-film foil suppliers materially reduce interruption risk and should be treated as positive catalysts.
  • Track partner contractual terms: Renewals and API supply agreements with Indivior and other partners directly affect AQST’s cost structure and operational flexibility.
  • Stress-test scenario planning: Model revenue sensitivity to temporary production halts caused by foil or API shortages; operational contingency plans are value-relevant.

If you want a tailored supplier risk briefing or to map AQST’s counterparty exposures across portfolios, start here: https://nullexposure.com/.

Conclusion: a manufacturing play with concentrated operational levers

Aquestive’s business is centered on manufacturing contracts that generate recurring revenue, but concentration in key inputs and a complex role mix create operational levers that materially affect cash flow execution. The company’s long-term leases and active, global supplier network reflect a mature manufacturing posture; however, the single-source packaging foil and partner-controlled API supply for marquee products constitute the primary near-term supply risks investors must monitor. For ongoing signals and supplier intelligence to support investment decisions, visit https://nullexposure.com/ for more analysis and alerts.